Community Navigator ATTR-CM & Sickle Cell Disease - Central
Company Overview
Pfizer has a longstanding commitment to advancing therapies that improve and extend patients’ lives. For 175 years, Pfizer has partnered with patients and advocates to develop breakthrough treatments, diverse clinical trials, educational materials, and support programs. The Specialty Care Patient Solutions team operates a patient advocacy support program spanning two critical therapeutic areas – Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Sickle Cell Disease (SCD) – designed to provide comprehensive care and innovative solutions that support patient journeys in both communities.
Position Summary
The Community Navigator (CN) is a remote, full-time role within the U.S. Patient Engagement Team, reporting to the Patient Engagement Director – ATTR & SCD as part of a national team of eight CNs (seven full-timeterritory-based CNs and one floater CN deployed across territories based on business need).
The CN serves as a guide for individuals living with ATTR-CM – representing the majority (approximately 85%) of the role’s focus – and for individuals living with Sickle Cell Disease (approximately 15%), along with their caregivers, helping them understand the treatment landscape and access available resources. This dual-therapeutic-area remit requires the CN to build and maintain disease-state fluency, community relationships, and resource knowledge across two distinct patient populations with different patient journeys, advocacy ecosystems, and community needs. This field-based, community-facing position emphasizes patient education, support, and connection to local, regional, and national community partners in both the ATTR-CM and SCD communities.
The CN is responsible for overseeing major programs, driving strategic initiatives, and working with cross-functional teams across both therapeutic areas. The CN has advanced expertise in the patient journey, which may inform organizational direction through key insights that contribute to long-term business objectives. The CN adheres to compliance & regulatory standards and fosters innovation to advance patient engagement. The CN is also accountable for measurable outcomes against defined KPIs spanning both therapeutic areas and plays a key role in shaping patient engagement strategies and solutions within the Specialty Care organization.
The CN does not assist with reimbursement support for Pfizer ATTR-CM or SCD treatments but appropriately triages patients to reimbursement resources as needed.
Key Responsibilities
-
Patient Education and Support: Educate patients and caregivers about ATTR-CM and SCD, treatment options, local and regional support offerings, and health and wellness resources. Provide ongoing education and disease state awareness throughout the patient journey, tailored to the distinct needs of each community.
-
Dual Therapeutic Area Coverage: Allocate time and effort across both therapeutic areas in line with team priorities (approximately 85% ATTR-CM / 15% SCD), maintaining current disease-state knowledge, approved resources, and community relationships in each; flex allocation as directed to meet evolving business and community needs.
-
Patient Navigation: Assist patients in navigating care by connecting them to relevant resources within their communities and at Pfizer , recognizing the distinct care pathways, sites of care, and support networks for ATTR-CM and SCD patients.
-
Health Equity: Engage thoughtfully with underserved communities, with particular attention to populations disproportionately affected by SCD, ensuring equitable access to education, resources, and support.
-
Collaboration: Coordinate with Key Account Directors, management, and cross-functional partners across two brand teams to ensure patient goals and support objectives align with local market dynamics and patient journeys in each therapeutic area.
-
Project Management: Set objectives, manage complex projects, and oversee ongoing acti
Get remote jobs like this by email
One weekly digest. No spam, unsubscribe anytime.